Javascript must be enabled to continue!
Ventricular tachycardia ablation in nonischemic cardiomyopathy
View through CrossRef
Abstract
Introduction
Catheter ablation outcomes for drug-resistant ventricular tachycardia (VT) in nonischemic cardiomyopathy (NICM) are suboptimal when compared to ischemic cardiomyopathy. We aimed to analyse the long-term efficacy and safety of percutaneous catheter ablation in this subset of patients.
Methods
Single-center observational retrospective registry including consecutive NICM patients who underwent catheter ablation for drug-resistant VT during a 10-year period. The efficacy endpoint was defined as VT-free survival after catheter ablation, while safety outcomes were defined by 30-days mortality and procedure-related complications. Independent predictors of VT recurrence were assessed by Cox regression.
Results
In a population of 68 patients, most were male (85%), mean left ventricular ejection fraction (LVEF) was 34±12%, and mean age was 58±15 years. All patients had an implantable cardioverter-defibrillator. Twenty-six (38%) patients underwent epicardial ablation (table 1). Over a median follow-up of 3 years (IQR 1–8), 41% (n=31) patients had VT recurrence and 28% died (n=19). Multivariate survival analysis identified LVEF (HR= 0.98; 95% CI 0.92–0.99, p=0.046) and VT storm at presentation (HR=2.38; 95% CI 1.04–5.46, p=0.041) as independent predictors of VT recurrence. The yearly rates of VT recurrence and overall mortality were 21%/year and 10%/year, respectively. No patients died at 30-days post-procedure, and mean hospital length of stay was 5±6 days. The complication rate was 7% (n=5, table 1), mostly in patients undergoing epicardial ablation (4 vs 1 in endocardial ablation, P=0.046).
Conclusion
LVEF and VT storm at presentation were independent predictors of VT recurrence in NICM patients after catheter ablation. While clinical outcomes can be improved with further technical and scientific development, a tailored endocardial/epicardial approach was safe, with low overall number of complications and no 30-days mortality.
Funding Acknowledgement
Type of funding sources: None.
Title: Ventricular tachycardia ablation in nonischemic cardiomyopathy
Description:
Abstract
Introduction
Catheter ablation outcomes for drug-resistant ventricular tachycardia (VT) in nonischemic cardiomyopathy (NICM) are suboptimal when compared to ischemic cardiomyopathy.
We aimed to analyse the long-term efficacy and safety of percutaneous catheter ablation in this subset of patients.
Methods
Single-center observational retrospective registry including consecutive NICM patients who underwent catheter ablation for drug-resistant VT during a 10-year period.
The efficacy endpoint was defined as VT-free survival after catheter ablation, while safety outcomes were defined by 30-days mortality and procedure-related complications.
Independent predictors of VT recurrence were assessed by Cox regression.
Results
In a population of 68 patients, most were male (85%), mean left ventricular ejection fraction (LVEF) was 34±12%, and mean age was 58±15 years.
All patients had an implantable cardioverter-defibrillator.
Twenty-six (38%) patients underwent epicardial ablation (table 1).
Over a median follow-up of 3 years (IQR 1–8), 41% (n=31) patients had VT recurrence and 28% died (n=19).
Multivariate survival analysis identified LVEF (HR= 0.
98; 95% CI 0.
92–0.
99, p=0.
046) and VT storm at presentation (HR=2.
38; 95% CI 1.
04–5.
46, p=0.
041) as independent predictors of VT recurrence.
The yearly rates of VT recurrence and overall mortality were 21%/year and 10%/year, respectively.
No patients died at 30-days post-procedure, and mean hospital length of stay was 5±6 days.
The complication rate was 7% (n=5, table 1), mostly in patients undergoing epicardial ablation (4 vs 1 in endocardial ablation, P=0.
046).
Conclusion
LVEF and VT storm at presentation were independent predictors of VT recurrence in NICM patients after catheter ablation.
While clinical outcomes can be improved with further technical and scientific development, a tailored endocardial/epicardial approach was safe, with low overall number of complications and no 30-days mortality.
Funding Acknowledgement
Type of funding sources: None.
Related Results
Case report: Para Hisian Atrial Tachycardia
Case report: Para Hisian Atrial Tachycardia
Atrial tachycardia accounts for around 10% of supraventricular tachycardias (1). Atrial tachycardia can either be focal or macrorenentrant. Focal AT usually start at a focal p...
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
Background
Takotsubo cardiomyopathy, also known as stress cardiomyopathy and broken heart syndrome, is a transient, non-ischemic cardiomyopathy marked by revers...
Impact of Catheter Ablation on Ventricular Tachycardia Recurrence in Patients with Chagas Cardiomyopathy Following implantable cardioverter-defibrillator Implantation: A Competing Risks Analysis
Impact of Catheter Ablation on Ventricular Tachycardia Recurrence in Patients with Chagas Cardiomyopathy Following implantable cardioverter-defibrillator Implantation: A Competing Risks Analysis
ABSTRACT
Background
Chagas cardiomyopathy (ChC) is a highly arrhythmogenic condition with frequent implantable cardioverter-def...
Ablation of left posterior fascicular tachycardia during sinus rhythm under the guide of non-contact array
Ablation of left posterior fascicular tachycardia during sinus rhythm under the guide of non-contact array
Aims
To explore the effectiveness and safety of catheter ablation for left posterior fascicular ventricular tachycardia under the guide of Ensite3000/array.
...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Ventricular tachycardia ablation in nonischemic cardiomyopathy
Ventricular tachycardia ablation in nonischemic cardiomyopathy
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION
...
Torsades de Pointes Following Ondansetron Administration: A Case Report with literature review
Torsades de Pointes Following Ondansetron Administration: A Case Report with literature review
Abstract
Introduction
Ondansetron blocks human ether-à-go-go-related gene (hERG) potassium channels, causing QT prolongation and risk of torsades de pointes (TdP). Despite its wide...
Nonischemic End-Systolic Performance
Nonischemic End-Systolic Performance
Nonischemic end-systolic performance decreases during ischemia. These changes in performance are likely to be dependent on the size and site of the ischemic zone, as well as the pr...

